InsidersTradesSigma
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
无可用的信号评分。
Explore the complete record of transactions filed by Erlander Mark. Director active across 1 company, notably Cardiff Oncology, Inc.. Cumulatively, 1 reports have been recorded. Breakdown: 1 buy · 0 sell. Total volume traded: €14k. History available since 25 November 2022. The latest transaction was filed on 25 November 2022 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 条申报中的 1 条